73027-79-9

Basic information

• Product Name: 4,6-Dichloronicotinic acid
• Synonyms: 2,4-DICHLORO-5-PYRIDINE-5-CARBOXYLIC ACID;2,4-DICHLORO-5-CARBOXYLPYRIDINE;2,4-DICHLOROPYRIDINE-5-CARBOXYLIC ACID;4,6-DICHLORONICOTINIC ACID;4,6-DICHLOROPYRIDINE-3-CARBOXYLIC ACID;2,4-Dichloro-5-carboxypyridine;2,4-Dichloro-5-pyridinecarboxylic acid;2,4-Dichloro-5-carboxylpyridine ,97%
• CAS NO: 73027-79-9
• Molecular Formula: C₆H₃Cl₂NO₂
• Molecular Weight: 192
• EINECS: -0
• Product Categories: Pyridine;Pyridines
• Mol File: 73027-79-9.mol

Chemical Properties

• Melting Point: 158-160
• Boiling Point: 336.997 °C at 760 mmHg
• Flash Point: 157.61 °C
• Appearance: /Solid
• Density: 1.612 g/cm³
• Vapor Pressure: 4.23E-05mmHg at 25°C
• Refractive Index: 1.605
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• PKA: 1.87±0.25(Predicted)
• Water Solubility: Slightly soluble in water.
• CAS DataBase Reference: 4,6-Dichloronicotinic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 4,6-Dichloronicotinic acid(73027-79-9)
• EPA Substance Registry System: 4,6-Dichloronicotinic acid(73027-79-9)

Safety Data

• Hazard Codes: Xi,Xn
• Statements: 22-20/21/22
• Safety Statements: 24/25-36/37
• HazardClass: IRRITANT
• Hazardous Substances Data: 73027-79-9(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
4,6-Dichloronicotinic acid is used as a key intermediate for the synthesis of various organic compounds. Its reactivity and functional groups make it suitable for the formation of new chemical bonds and the creation of a wide range of products.
Used in Pharmaceutical Industry:
4,6-Dichloronicotinic acid is used as a building block in the development of pharmaceuticals. Its unique structure allows it to be incorporated into drug molecules, potentially enhancing their therapeutic properties and effectiveness in treating various medical conditions.
Used in Agrochemicals:
4,6-Dichloronicotinic acid is used as a raw material in the production of agrochemicals, such as pesticides and herbicides. Its chemical properties enable it to be formulated into effective products for controlling pests and weeds in agricultural settings.
Used in Dye Industry:
4,6-Dichloronicotinic acid is used as an intermediate in the synthesis of dyes. Its ability to form stable chemical bonds with other compounds allows for the creation of a variety of dyes with different colors and properties, suitable for various applications in textiles, printing, and other industries.

InChI:InChI=1/C6H3Cl2NO2/c7-4-1-5(8)9-2-3(4)6(10)11/h1-2H,(H,10,11)

Upstream product

• 40296-46-6 ethyl 4,6-dichloronicotinate 
• 124-38-9 carbon dioxide 
• 343781-49-7 2,4-dichloro-5-iodopyridine 
• 109-09-1 2-chloropyridine 
• 26452-80-2 2,4-dichloropyridine 
• 153034-86-7 2-chloro-4-iodopyridine 
• 78607-36-0 2-chloro-3-iodopyridine 
• 343781-36-2 2,4-dichloro-3-iodo-pyridine 
• 6975-44-6 4,6-dihydroxynicotinic acid ethyl ester 
• 65973-52-6 methyl 4,6-dichloropyridine-3-carboxylate 
• 105-50-0 diethyl 1,3-acetonedicarboxylate 
• 79398-27-9 methyl 4,6-dihydroxypyridine-3-carboxylate 
• 1830-54-2 3-oxopentanedioic acid dimethyl ester 

Downstream Products

• 166526-03-0 4,6-dichloropyridine-3-carbonitrile 
• 107836-75-9 4,6-dichloropyridine-3-carbonyl chloride 
• 55934-01-5 2,3,5-trichloropyridine 
• 847608-22-4 4-(4-bromo-2-chlorophenylamino)-6-chloronicotinic acid hydrochloride salt 
• 70593-57-6 4,6-dichloro-nicotinamide 
• 1040246-72-7 6-dichloro-4-(2-fluoro-4-iodophenylamino)nicotinic acid 
• 847373-07-3 4-(4-bromo-2-chloro-phenylamino)-6-chloro-nicotinic acid 
• 1093955-77-1 C₁₆H₁₆ClNO₄ 
• 716362-10-6 6-chloro-4-methoxypyridine-3-carboxylic acid 
• 862170-57-8 4-[(4,6-dichloro-3-pyridinyl)carbonyl]benzonitrile 
• 862170-55-6 (4,6-dichloro-3-pyridinyl)(4-fluorophenyl)methanone 
• 862170-51-2 (4,6-dichloro-3-pyridinyl)-[4-(methyloxy)phenyl]methanone 
• 1540715-31-8 C₁₄H₈Cl₂F₂O 
• 1254216-71-1 6-(4-fluoro-3-(pyrrolidine-1-carboxamido)phenylamino)-4-(pyridin-3-ylmethylamino)nicotinamide 

Relevant articles and documents

Synthesis and SAR studies of novel 1,2,4-oxadiazole-sulfonamide based compounds as potential anticancer agents for colorectal cancer therapy

A diverse series of 1,2,4-oxadiazoles based substituted compounds were designed, synthesized and evaluated as anticancer agents targeting carbonic anhydrase IX (CAIX). Initial structure-activity analysis suggested that the thiazole/thiophene-sulfonamide conjugates of 1,2,4-oxadiazoles exhibited potent anticancer activities with low μM potencies. Compound OX12 exhibited antiproliferative activity (IC50 = 11.1 μM) along with appreciable inhibition potential for tumor-associated CAIX (IC50 = 4.23 μM) isoform. Therefore, OX12 was structurally optimized and its SAR oriented derivatives (OX17-27) were synthesized and evaluated. This iteration resulted in compound OX27 with an almost two-fold increase in antiproliferative effect (IC50 = 6.0 μM) comparable to the clinical drug doxorubicin and significantly higher potency against CAIX (IC50 = 0.74 μM). Additionally, OX27 treatment decreases the expression of CAIX, induces apoptosis and ROS production, inhibited colony formation and migration of colon cancer cells. Our studies provide preclinical rational for the further optimization of identified OX27 as a suitable lead for the possible treatment of CRC.

Novel approach towards 3,7-disubstituted 1,6-naphthyridin-4(1H)-ones exploiting cross-coupling and SNAr reactions of a dihalogenated compound

A new route towards the synthesis of a series of 3,7-disubstituted 1,6-naphthyridin-4(1H)-ones in moderate to good yields is reported. The strategy involves the preparation of a 3,7-dihalogenated compound that undergoes differential functionalization using palladium-catalyzed cross-coupling and SNAr reactions.

Discovery and structure-based design of 4,6-diaminonicotinamides as potent and selective IRAK4 inhibitors

The identification of small molecule inhibitors of IRAK4 for the treatment of autoimmune diseases has been an area of intense research. We discovered novel 4,6-diaminonicotinamides which potently inhibit IRAK4. Optimization efforts were aided by X-ray crystal structures of inhibitors bound to IRAK4. Structure activity relationship (SAR) studies led to the identification of compound 29 which exhibited sub-micromolar potency in a LTA stimulated cellular assay.

HETEROARYL SUBSTITUTED AMINOPYRIDINE COMPOUNDS

Disclosed are compounds of Formula (I) Formula(I) or salts thereof, wherein HET is a heteroaryl selected from oxazolyl, pyrazolyl, imidazo[l,2-b]pyridazin-3-yl, and pyrazolo[l,5-a]pyrimidin-3-yl, wherein said heteroaryl is attached to the pyridinyl group in the compound of Formula (I) by a carbon ring atom in the heteroaryl and wherein said heteroaryl is substituted with zero to 2 Rb; and R1, R3, and Rb are define herein. Also disclosed are methods of using such compounds as modulators of IRAK4, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing inflammatory and autoimmune diseases, or in the treatment of cancer.

Quinolone amides as antitrypanosomal lead compounds with In Vivo activity

Human African trypanosomiasis (HAT) is a major tropical disease for which few drugs for treatment are available, driving the need for novel active compounds. Recently, morpholino-substituted benzyl amides of the fluoroquinolone-type antibiotics were identified to be compounds highly active against Trypanosoma brucei brucei. Since the lead compound GHQ168 was challenged by poor water solubility in previous trials, the aim of this study was to introduce structural variations to GHQ168 as well as to formulate GHQ168 with the ultimate goal to increase its aqueous solubility while maintaining its in vitro antitrypanosomal activity. The pharmacokinetic parameters of spray-dried GHQ168 and the newly synthesized compounds GHQ242 and GHQ243 in mice were characterized by elimination half-lives ranging from 1.5 to 3.5 h after intraperitoneal administration (4 mice/compound), moderate to strong human serum albumin binding for GHQ168 (80%) and GHQ243 (45%), and very high human serum albumin binding (>99%) for GHQ242. For the lead compound, GHQ168, the apparent clearance was 112 ml/h and the apparent volume of distribution was 14 liters/kg of body weight (BW). Mice infected with T. b. rhodesiense (STIB900) were treated in a stringent study scheme (2 daily applications between days 3 and 6 postinfection). Exposure to spray-dried GHQ168 in contrast to the control treatment resulted in mean survival durations of 17 versus 9 days, respectively, a difference that was statistically significant. Results that were statistically insignificantly different were obtained between the control and the GHQ242 and GHQ243 treatments. Therefore, GHQ168 was further profiled in an early-treatment scheme (2 daily applications at days 1 to 4 postinfection), and the results were compared with those obtained with a control treatment. The result was statistically significant mean survival times exceeding 32 days (end of the observation period) versus 7 days for the GHQ168 and control treatments, respectively. Spray-dried GHQ168 demonstrated exciting antitrypanosomal efficacy.

AROMATIC COMPOUND

Provided is a novel aromatic ring compound having a GPR40 agonist activity and a GLP-1 secretagogue action. A compound represented by the formula: wherein each symbol is as described in the DESCRIPTION, or a salt thereof has a GPR40 agonist activity and a GLP-1 secretagogue action, is useful for the prophylaxis or treatment of cancer, obesity, diabetes, hypertension, hyperlipidemia, cardiac failure, diabetic complications, metabolic syndrome, sarcopenia and the like, and affords superior efficacy.

HETEROARYL SUBSTITUTED NICOTINAMIDE COMPOUNDS

Disclosed are compounds of Formula (I) or salts thereof, wherein: HET is a heteroaryl selected from pyrazolyl, indolyl, pyrrolo[2,3-b]pyridinyl, pyrrolo[2,3-d]pyrimidinyl, pyrazolo[3,4-b]pyridinyl, pyrazolo[3,4-d]pyrimidinyl, 2,3-dihydro-1H-pyrrolo[2,3-b]pyridinyl, imidazo[4,5-b]pyridinyl, and purinyl, wherein said heteroaryl is substituted with Ra and Rb; and R1 and R2 are define herein. Also disclosed are methods of using such compounds as modulators of IRAK4, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing inflammatory and autoimmune diseases.

QUINAZOLINONE DERIVATIVE

PROBLEM TO BE SOLVED: To provide a novel compound having effects on 5-HT5A receptor and useful as a therapeutic agent and/or a preventive agent of psychiatric disorders and neurodegenerative diseases to which 5-HT5A receptor relates such as schizophrenia,

COMPOUNDS AND METHODS OF USE

This disclosure provides compounds and compositions and methods of using those compounds and compositions to treat diseases and disorders associated with excessive transforming growth factor-beta (TGFβ) activity. This disclosure also provides methods of using the compounds in combination with one or more cancer immunotherapies.

MULTIPLE KINASE PATHWAY INHIBITORS

Kinase with inhibitory activity against kinases disposed in multiple signaling pathways and their therapeutic uses.